Therapeutic efficacy of mesenchymal stem cells for cardiovascular diseases

IF 1.6 Q2 MEDICINE, GENERAL & INTERNAL Journal of Mind and Medical Sciences Pub Date : 2021-10-11 DOI:10.22543/7674.82.p179190
Dragana Miloradovic, D. Pavlovic, M. Stojkovic, S. Bojic, V. Volarevic, M. Jankovic, B. Ljujic
{"title":"Therapeutic efficacy of mesenchymal stem cells for cardiovascular diseases","authors":"Dragana Miloradovic, D. Pavlovic, M. Stojkovic, S. Bojic, V. Volarevic, M. Jankovic, B. Ljujic","doi":"10.22543/7674.82.p179190","DOIUrl":null,"url":null,"abstract":"Despite the improvements in pharmacological and surgical treatments, cardiovascular diseases (CVDs) are the number one cause of death worldwide. During the last two decades, the search for new therapies has been revolutionized with the growing knowledge of stem cell biology. Due to their huge differentiation capacity and paracrine effects, mesenchymal stem cells (MSCs) are a promising tool for the treatment of CVDs. The encouraging outcomes of preclinical studies using MSCs as a treatment for diseased myocardium have set the scene for worldwide clinical trials. In this review, we overview either complete or ongoing clinical trials using MSCs for the therapy of CVDs. In particular, we analyze the biological properties of MSCs, elucidate recent clinical findings and clinical trial phases of investigation, highlight clinical therapeutic effects of MSCs, and discuss challenges towards the clinical use of these cells in the therapy of CVDs.","PeriodicalId":43987,"journal":{"name":"Journal of Mind and Medical Sciences","volume":" ","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2021-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Mind and Medical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22543/7674.82.p179190","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 2

Abstract

Despite the improvements in pharmacological and surgical treatments, cardiovascular diseases (CVDs) are the number one cause of death worldwide. During the last two decades, the search for new therapies has been revolutionized with the growing knowledge of stem cell biology. Due to their huge differentiation capacity and paracrine effects, mesenchymal stem cells (MSCs) are a promising tool for the treatment of CVDs. The encouraging outcomes of preclinical studies using MSCs as a treatment for diseased myocardium have set the scene for worldwide clinical trials. In this review, we overview either complete or ongoing clinical trials using MSCs for the therapy of CVDs. In particular, we analyze the biological properties of MSCs, elucidate recent clinical findings and clinical trial phases of investigation, highlight clinical therapeutic effects of MSCs, and discuss challenges towards the clinical use of these cells in the therapy of CVDs.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
间充质干细胞治疗心血管疾病的疗效
尽管在药物和手术治疗方面有所改进,但心血管疾病(cvd)仍是全球头号死亡原因。在过去的二十年中,随着干细胞生物学知识的增长,对新疗法的探索已经发生了革命性的变化。间充质干细胞(mesenchymal stem cells, MSCs)由于其巨大的分化能力和旁分泌作用,是治疗心血管疾病的一种很有前景的工具。使用间充质干细胞治疗病变心肌的临床前研究的令人鼓舞的结果为世界范围的临床试验奠定了基础。在这篇综述中,我们综述了使用MSCs治疗心血管疾病的已完成或正在进行的临床试验。特别地,我们分析了MSCs的生物学特性,阐明了最近的临床发现和临床试验的研究阶段,强调了MSCs的临床治疗效果,并讨论了这些细胞在心血管疾病治疗中的临床应用所面临的挑战。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Mind and Medical Sciences
Journal of Mind and Medical Sciences MEDICINE, GENERAL & INTERNAL-
自引率
61.10%
发文量
37
审稿时长
8 weeks
期刊最新文献
Prevalence of depression, anxiety and stress after the COVID-19 pandemic period among students at the Medical University of Sofia; Significance of demographic, educational, and pandemic-related variables Sarcopenic obesity, pathogenesis, and treatment with a focus on exercise and protein intake Gastric cancer; actualities and perspectives of early diagnosis and targeted therapy Barrett's esophagus as a premalignant condition; medical and surgical therapeutic management Coxarthrosis etiology influences the patients’ quality of life in the preoperative and postoperative phase of total hip arthroplasty
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1